Respiratory Syncytial Virus Vaccine Approaches: a Current Overview

Clark, Carolyn M.; Guerrero-Plata, Antonieta

doi:10.1007/s40588-017-0074-6

Cited by 12 publications

(12 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[72][73][74] Memories of such disease enhancement postvaccination strongly influenced subsequent RSV F protein subunit vaccine development and trial design. 75 The development of a safe and efficacious SARS-CoV-2 vaccine will require the development of vaccine candidates that take into account the risk of similar vaccineassociated immunopathology.…”

Section: Vaccine-induced Immunopathology Linked To Coronavirusesmentioning

confidence: 99%

Eosinophil responses during COVID-19 infections and coronavirus vaccination

Lindsley

Schwartz

Rothenberg

2020

Journal of Allergy and Clinical Immunology

309

312

View full text Add to dashboard Cite

Eosinophils are circulating and tissue-resident leukocytes that have potent proinflammatory effects in a number of diseases. Recently, eosinophils have been shown to have various other functions, including immunoregulation and antiviral activity. Eosinophil levels vary dramatically in a number of clinical settings, especially following eosinophil-targeted therapy, which is now available to selectively deplete these cells. There are key coronavirus disease 2019 (COVID-19)-related questions concerning eosinophils whose answers affect recommended prevention and care. First, do patients with eosinophiliaassociated diseases have an altered course of COVID-19? Second, do patients with eosinopenia (now intentionally induced by biological drugs) have unique COVID-19 susceptibility and/ or disease course? This is a particularly relevant question because eosinopenia is associated with acute respiratory deterioration during infection with the severe acute respiratory syndrome coronavirus 2, the causative agent of COVID-19. Third, do eosinophils contribute to the lung pathology induced during COVID-19 and will they contribute to immunopotentiation potentially associated with emerging COVID-19 vaccines? Herein, we address these timely questions and project considerations during the emerging COVID-19 pandemic.

show abstract

Section: Vaccine-induced Immunopathology Linked To Coronavirusesmentioning

confidence: 99%

Eosinophil responses during COVID-19 infections and coronavirus vaccination

Lindsley

Schwartz

Rothenberg

2020

Journal of Allergy and Clinical Immunology

309

312

View full text Add to dashboard Cite

show abstract

“…Eosinophil-associated type 2 inflammation also occurred with SARS-CoV-1 reinfection in monkeys [13]. Eosinophil-associated pulmonary disease was also seen subsequent to infection after RSV vaccination [14]. Therefore, there is the possibility that SARS-CoV-2 vaccines might cause a similar vaccine-associated immunopathology.…”

Section: Covid-19 and Eosinophilsmentioning

confidence: 99%

Strategies to Prevent SARS-CoV-2-Mediated Eosinophilic Disease in Association with COVID-19 Vaccination and Infection

Simon

Karaulov

Bachmann

2020

Int Arch Allergy Immunol

View full text Add to dashboard Cite

A vaccine to protect against COVID-19 is urgently needed. Such a vaccine should efficiently induce high-affinity neutralizing antibodies which neutralize SARS-CoV-2, the cause of COVID-19. However, there is a concern regarding both vaccine-induced eosinophilic lung disease and eosinophilassociated Th2 immunopotentiation following infection after vaccination. Here, we review the anticipated characteristics of a COVID-19 vaccine to avoid vaccine-associated eosinophil immunopathology.

show abstract

“…Respiratory syncytial virus (RSV), a negative-sense single-stranded enveloped RNA virus, is a global human pathogen responsible for lower respiratory tract infections and is considered as the major viral pathogen of the lower respiratory tract of infants. Therefore, there are urgent need to utilize convenient strategies to prevent RSV infection, including beside of live attenuated, chimeric, and subunit vaccines also nanosized particles (Borchers et al 2013;Clark and Guerrero-Plata 2017).…”

Section: Respiratory Syncytial Virusmentioning

confidence: 99%

Nanoformulations: A Valuable Tool in the Therapy of Viral Diseases Attacking Humans and Animals

Jampílek

Kráľová

2019

Nanotheranostics

View full text Add to dashboard Cite

Various viruses can be considered as one of the most frequent causes of human diseases, from mild illnesses to really serious sicknesses that end fatally. Numerous viruses are also pathogenic to animals and plants, and many of them, mutating, become pathogenic also to humans. Several cases of affecting humans by originally animal viruses have been confirmed. Viral infections cause significant morbidity and mortality in humans, the increase of which is caused by general immunosuppression of the world population, changes in climate, and overall globalization. In spite of the fact that the pharmaceutical industry pays great attention to human viral infections, many of clinically used antivirals demonstrate also increased toxicity against human cells, limited bioavailability, and thus, not entirely suitable therapeutic profile. In addition, due to resistance, a combination of antivirals is needed for life-threatening infections. Thus, the development of new antiviral agents is of great importance for the control of virus spread. On the other hand, the discovery and development of structurally new antivirals represent risks. Therefore, another strategy is being developed, namely the reformulation of existing antivirals into nanoformulations and investigation of various metal and metalloid nanoparticles with respect to their diagnostic, prophylactic, and therapeutic antiviral applications. This chapter is focused on nanoscale materials/formulations with the potential to be used for the treatment or inhibition of the spread of viral diseases caused by human immunodeficiency virus, influenza A viruses (subtypes H3N2 and H1N1), avian influenza and swine influenza viruses, respiratory syncytial virus, herpes simplex virus, hepatitis B and C viruses, Ebola and Marburg viruses, Newcastle disease virus, dengue and Zika viruses, and pseudorabies virus. Effective antiviral long-lasting and target-selective nanoformulations developed for oral, intravenous, intramuscular, intranasal, intrarectal, intravaginal, and intradermal applications are discussed.

show abstract

Respiratory Syncytial Virus Vaccine Approaches: a Current Overview

Cited by 12 publications

References 43 publications

Eosinophil responses during COVID-19 infections and coronavirus vaccination

Eosinophil responses during COVID-19 infections and coronavirus vaccination

Strategies to Prevent SARS-CoV-2-Mediated Eosinophilic Disease in Association with COVID-19 Vaccination and Infection

Nanoformulations: A Valuable Tool in the Therapy of Viral Diseases Attacking Humans and Animals

Contact Info

Product

Resources

About